New SVP COO Strengthens Outcomes’ Executive Leadership Team
ALPHARETTA, Ga. — Outcomes Health Information Solutions, LLC, a leading healthcare data
abstraction and analytics company, today named Hassan Rifaat, M.D., as
the new Senior Vice President and Chief Operating Officer. “We are
excited to have Dr. Rifaat join our organization. As a physician with
over 20 years of senior level experience with leading national
healthcare organizations, Dr. Rifaat will bring additional experience,
ideas and knowledge to our operations and clinical team,” says Outcomes’
CEO, Gary Velasquez. “Having a physician as our SVP COO demonstrates
Outcomes’ commitment to superior clinical abstraction quality and
business operations, strengthening our platform for continued growth.”
Prior to joining Outcomes, Dr. Rifaat served as Senior Vice President at
Coventry Health Care where he managed seven health plans with over 1,500
employees in 11 states. Coventry Health Care is a national managed
healthcare company based in Bethesda, Maryland operating health plans,
insurance companies, network rental/managed care and workers
compensation services companies. In addition, Dr. Rifaat has held
several senior executive positions at Humana, Inc.; a $12 billion
managed care company, where he served as Regional CEO over Illinois
the Southeast, Market President for Louisiana, and Director, Clinical
Innovation. He also was Vice President of Marketing and Sales for
HealthMarket and held executive level positions at Alignis, Oxford
Health Plans, and Texas Health Innovators.
Dr. Rifaat graduated Cum Laude from Harvard University with an AB in
Biochemistry and obtained his Medical Doctor degree from the University
of Virginia School of Medicine.
As Outcomes’ SVP COO, Dr. Rifaat will manage the day-to-day
operational and clinical activities on a company-wide basis. He will
administer, direct, and coordinate all operational activities of the
company including planning, design and process improvement.
Positions Merck to Capitalize on Opportunities for Global Growth
WHITEHOUSE STATION, N.J. — Merck Co., Inc. (NYSE: MRK), known outside the U.S. and Canada as MSD,
today provided further detail on integration plans for the companys
research and development, manufacturing and other business operations as
part of a global restructuring program announced following the November
2009 merger of Merck and Schering-Plough. The consolidation plans
support Mercks strategic direction as a customer focused, innovative
and diversified global health care company, and position the company to
invest in key areas for future growth, including emerging markets,
biologics, vaccines and consumer care.
Merck today announced plans to phase out operations at eight research
sites and eight manufacturing sites, as well as to continue to
consolidate office facilities worldwide, as part of the global merger
restructuring program that began last December. The goal of the
restructuring is to create a flexible RD organization that cultivates
scientific innovation, facilitates external collaboration and drives
pipeline progress and a reliable, more fully utilized and cost efficient
worldwide manufacturing supply chain to support Mercks broader product
portfolio.
Merck continues to expect its total workforce to be reduced by
approximately 15 percent across all areas of the combined company
worldwide as part of the initial phases of its merger restructuring
program. The company said it will continue to hire new employees in
strategic growth areas of the business as necessary.
“Today’s announcement is another important step as we successfully
integrate our global operations on schedule and move forward with
Mercks strategic priorities,” said Richard T. Clark, chairman and chief
executive officer of Merck. “These changes are crucial to drive future
growth and realize the promise of being a global health care leader for
the long term. While we believe these actions are necessary to support
Mercks competitive advantage, they required difficult decisions that
will impact some of our colleagues, their families and local
communities. We will implement our restructuring plans with the utmost
care and respect for the hard-working and talented employees of Merck,”
he said.
Medicare Beneficiaries Whose High Prescription Drug Costs Have Put
Them in the Medicare Part D Donut Hole to Receive $250 Rebate Checks as
a Result of the Affordable Care Act
WASHINGTON — The next round of more than 300,000 eligible seniors who have entered
the Medicare Part D “donut hole” this year have been mailed their
tax-free, one time rebate check for $250, U.S. Department of Health and
Human Services Secretary Kathleen Sebelius announced today .
These one-time rebate checks are the first step in closing
the prescription drug coverage gap under the Affordable Care Act. The
first round of checks were distributed in the middle of June. As
qualifying Medicare recipients “fall into the donut hole,” they will be
sent a rebate check by Medicare.
“Seniors and other Medicare recipients in the Medicare donut hole are
struggling to afford the medications they need and their basic living
expenses. Seventy percent of our first round of these $250 rebate checks
were cashed within a week of eligible Medicare recipients receiving
them; so, we know that folks really need some help,” said Secretary
Sebelius. “The Affordable Care Act starts to close the donut hole this
year, giving much-needed relief to millions of seniors. In 2011, the
Affordable Care Act takes an additional step for Medicare beneficiaries
in the donut hole by providing them with a 50 percent discount on their
brand name medications. Every year from 2012 until 2020, the Affordable
Care Act will take progressive steps to close the donut hole.”
On Thursday, July 8, at 2:00 p.m., HHS Secretary Kathleen Sebelius will
join local officials in Manchester, N.H., for a forum with senior
citizens to discuss the rebate checks and other benefits of the
Affordable Care Act as well as efforts to fight Medicare fraud.
Double Eyelid Surgery Singapore
tags: Uncategorized author: admin comments: No Comments